Randomized, Controlled Trial - Lactoferrin Prevention of Diarrhea in Children - Full Text View

Purpose

Much has been learned in recent years about the mechanisms by which breastfeeding improves child health and survival. However, there has been little progress in using these insights to improve pediatric care. Factors that are important for protecting the breast fed infant might be expected to decrease the adverse effects of weaning on diarrhea, growth, and development. The proposed study is meant to begin addressing this important gap by a clinical trial of lactoferrin supplementation in previously weaned children. Lactoferrin,an iron-binding protein with multiple physiological functions (anti-microbial, anti-inflammatory, and immunomodulatory), is one of the most important proteins present in mammalian milk. Our hypothesis is that lactoferrin (given as a daily supplement in amounts similar to those consumed if the child were still breastfed) will improve health by mimicking its protective roles in milk. The significance of these studies is that they will prove feasibility of improving child health after the end of breastfeeding by continuing ingestion of a major protective milk protein. Diarrhea and malnutrition after weaning is a global problem that may be amenable to this approach.

Condition	Intervention	Phase
Diarrhea Malnutrition	Dietary Supplement: bovine lactoferrin Dietary Supplement: placebo [maltodextrin]	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Prevention
Official Title:	Randomized, Controlled Trial - Lactoferrin Prevention of Diarrhea in Children

Resource links provided by NLM:

MedlinePlus related topics: Diarrhea Malnutrition

U.S. FDA Resources

Further study details as provided by Thomas G Cleary, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):

Primary Outcome Measures:

Determination of the effect of bovine lactoferrin supplementation on prevention of diarrhea,measured by the number of episodes of diarrhea during a 6 month trial in previously weaned Peruvian children enrolled at 12 to 18 months of age. [ Time Frame: 6 months ]

Secondary Outcome Measures:

Determination of the effect of bovine lactoferrin supplementation on growth. [ Time Frame: 6 months ]


Enrollment:	555
Study Start Date:	February 2008
Study Completion Date:	October 2011
Primary Completion Date:	May 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: A This group will receive daily lactoferrin supplementation	Dietary Supplement: bovine lactoferrin 1gm of lactoferrin will be given each day
Placebo Comparator: B placebo	Dietary Supplement: placebo [maltodextrin] placebo that appears identical to lactoferrin will be given daily

Detailed Description:

The proposed community-based study will be conducted in a previously weaned population at risk for repeated intestinal infections. Infants who are 12-18 months of age living in the District of Independencia, Lima, Peru will be eligible for enrollment. We will conduct a randomized double blind placebo controlled trial comparing twice daily supplementation with bovine lactoferrin versus a placebo (maltodextrin) Therapy will be continued for 6 months with close monitoring of all study participants for diarrhea and growth.

Specific aim 1: Determine the effect of bovine lactoferrin supplementation on prevention of diarrhea,measured by the number of episodes of diarrhea during a 6 month trial in previously weaned Peruvian children enrolled at 12 to 18 months of age.

Specific aim 2: Determine the effect of bovine lactoferrin supplementation on growth.

Eligibility


Ages Eligible for Study:	12 Months to 18 Months (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Infants 12 to 18 months of age from the Outpatient clinics (Puestos de Salud) of Districto de Independencia in Lima, Peru will be eligible for enrollment in this study.
Infants previously weaned for at least one week will be eligible for study.

Exclusion Criteria:

Infants with either exclusive or partial breast-feeding will not be enrolled; mothers will be encouraged to continue breastfeeding.
Infants ill with severe, persistent or chronic diarrhea will be excluded.
Infants with severe malnutrition (defined as weight-for-height < -3 SDs, height-for-age < -3SDs)will be excluded.
Infants with a serious infections that required hospitalization 1 month prior (e.g. meningitis,pneumonia, bacteremia) will be excluded.
Infants with known HIV (data from parent or medical records) will be excluded.
Infants with underlying chronic illness (e.g. malignancy, immunosuppression, chronic renal failure, congestive heart failure, liver failure) will be excluded.
Infants with history of allergy to cow's milk or infant formula, eczema, allergic rhinitis or asthma will be excluded.
Infants with a family history of eczema, allergic rhinitis, asthma, or milk intolerance will be excluded.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00560222

Locations


Peru
Universidad Peruana Cayetana Heredia
Lima, Peru

Sponsors and Collaborators

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Investigators


Principal Investigator:	Thomas G Cleary, MD	University of Texas School of Public Health - Houston

More Information

Publications:

Ochoa TJ, Noguera-Obenza M, Cleary TG. Lactoferrin blocks the initial host cell attachment mechanism of Enteropathogenic E. coli (EPEC). Adv Exp Med Biol. 2004;554:463-6.

Ochoa TJ, Noguera-Obenza M, Ebel F, Guzman CA, Gomez HF, Cleary TG. Lactoferrin impairs type III secretory system function in enteropathogenic Escherichia coli. Infect Immun. 2003 Sep;71(9):5149-55.

Ochoa TJ, Brown EL, Guion CE, Chen JZ, McMahon RJ, Cleary TG. Effect of lactoferrin on enteroaggregative E. coli (EAEC). Biochem Cell Biol. 2006 Jun;84(3):369-76.

Gomez HF, Ochoa TJ, Carlin LG, Cleary TG. Human lactoferrin impairs virulence of Shigella flexneri. J Infect Dis. 2003 Jan 1;187(1):87-95. Epub 2002 Dec 13.

Gomez HF, Ochoa TJ, Herrera-Insua I, Carlin LG, Cleary TG. Lactoferrin protects rabbits from Shigella flexneri-induced inflammatory enteritis. Infect Immun. 2002 Dec;70(12):7050-3.

Gomez HF, Herrera-Insua I, Siddiqui MM, Diaz-Gonzalez VA, Caceres E, Newburg DS, Cleary TG. Protective role of human lactoferrin against invasion of Shigella flexneri M90T. Adv Exp Med Biol. 2001;501:457-67.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ochoa TJ, Chea-Woo E, Baiocchi N, Pecho I, Campos M, Prada A, Valdiviezo G, Lluque A, Lai D, Cleary TG. Randomized double-blind controlled trial of bovine lactoferrin for prevention of diarrhea in children. J Pediatr. 2013 Feb;162(2):349-56. doi: 10.1016/j.jpeds.2012.07.043. Epub 2012 Aug 30.


Responsible Party:	Thomas G Cleary, Professor, Division of Epidemiology, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier:	NCT00560222 History of Changes
Other Study ID Numbers:	1R01HD051716-01A2 ( U.S. NIH Grant/Contract )
Study First Received:	November 15, 2007
Last Updated:	October 31, 2011

Keywords provided by Thomas G Cleary, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):


randomized controlled trial lactoferrin children	diarrhea malnutrition growth

Additional relevant MeSH terms:


Diarrhea Malnutrition Signs and Symptoms, Digestive Signs and Symptoms	Nutrition Disorders Lactoferrin Anti-Infective Agents

ClinicalTrials.gov processed this record on September 25, 2017